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Abstract
Background: Perivascular macrophages and microglia are critical to CNS function. Drugs of abuse increase
extracellular dopamine in the CNS, exposing these cells to elevated levels of dopamine. In rodent macrophages and
human T-cells, dopamine was shown to modulate cellular functions through activation of dopamine receptors and
other dopaminergic proteins. The expression of these proteins and the effects of dopamine on human macrophage
functions had not been studied.
Methods: To study dopaminergic gene expression, qRT-PCR was performed on mRNA from primary human
monocyte derived macrophages (MDM). Expression and localization of dopaminergic proteins was examined by
immunoblotting isolated plasma membrane, total membrane and cytosolic proteins from MDM. To characterize
dopamine-mediated changes in cytokine production in basal and inflammatory conditions, macrophages were
treated with different concentrations of dopamine in the presence or absence of LPS and cytokine production was
assayed by ELISA. Statistical significance was determined using two-tailed Students’ T-tests or Wilcoxen Signed Rank
tests.
Results: These data show that MDM express mRNA for all five subtypes of dopamine receptors, and that dopamine
receptors 3 and 4 are expressed on the plasma membrane. MDM also express mRNA for the dopamine transporter
(DAT), vesicular monoamine transporter 2 (VMAT2), tyrosine hydroxylase (TH) and aromatic amino acid
decarboxylase (AADC). DAT is expressed on the plasma membrane, VMAT2 on cellular membranes and TH and
AADC are in the cytosol. Dopamine also alters macrophage cytokine production in both untreated and LPS-treated
cells. Untreated macrophages show dopamine mediated increases IL-6 and CCL2. Macrophages treated with LPS
show increased IL-6, CCL2, CXCL8 and IL-10 and decreased TNF-α.
Conclusions: Monocyte derived macrophages express dopamine receptors and other dopaminergic proteins
through which dopamine may modulate macrophage functions. Thus, increased CNS dopamine levels due to drug
abuse may exacerbate the development of neurological diseases including Alzheimer’s disease and HIV associated
neurological disorders.
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Background
In individuals who abuse drugs such as cocaine and meth-
amphetamine [1,2], extracellular dopamine in different
regions of the brain is increased, exposing perivascular
macrophages and microglia to elevated concentrations of
dopamine [3-5]. Central nervous system (CNS) dopa-
mine is also increased by therapeutic drugs including
antidepressants [6], L-DOPA [7,8], methylphenidate [9],
cholinergic agents for treatment of Alzheimer’s disease
[10], as well as by stress [11], depression [12,13] and neu-
ropathologies such as HIV-associated neurological disor-
ders (HAND) [14] and schizophrenia [15,16]. Little is
known about the effects of dopamine on human macro-
phages, although studies in rodent macrophages and
microglia, as well as in human T-cells indicate that ex-
posure to high concentrations of dopamine significantly
impacts the function of macrophages and microglia [17-
24]. Perivascular macrophages and microglia are central
to CNS function [25], and dysfunction in these cell types
is associated with the development of many neurological
disorders [26,27]. Therefore, we characterized the macro-
phage dopaminergic system and examined the effects of
dopamine on macrophages to define mechanisms by
which increases in CNS dopamine may contribute to the
development of neuropathology.
Dopamine is synthesized by conversion of tyrosine to
L-DOPA by the enzyme tyrosine hydroxylase (TH), and
L-DOPA is then converted to dopamine by aromatic
amino acid decarboxylase (AADC) [28,29]. Dopamine
acts through activation of dopamine receptors (DR),
which are divided into two sub-classes, D1-like dopamine
receptors, D1R and D5R, and D2-like dopamine recep-
tors, D2R, D3R and D4R [30]. Dopamine receptor activa-
tion depends on CNS dopamine concentrations, which
are regulated by dopamine transporter (DAT)-mediated
re-uptake, metabolic breakdown by monoamine oxidases
and catechol-O-methyl transferase, and diffusion into
extracellular fluid [31-34]. Recaptured or newly synthe-
sized dopamine is transported from the cytoplasm into
secretory granules by vesicular monoamine transporters
(VMAT), where it is stored until released [35]. Thus, the
dopaminergic proteins DAT, VMAT, TH and AADC act
together with DR to regulate the effects of dopamine.
Dopamine receptors are expressed on human T-cells,
neutrophils, monocytes and B-cells [36]. T-cells also
express TH and DAT, and take up, store, and
synthesize dopamine as part of their regulatory pro-
cesses [17,37-39]. Dopamine mediates proliferation,
quiescence, chemotaxis and cytokine production in dif-
ferent subtypes of human T-cells [20,21,40-43] and also
modulates neutrophil migration and apoptosis [44,45].
Expression of DAT, VMAT2 and AADC were detected
in human myeloid cells as well as the promyelocytic
U937 cell line [46,47]. Tyrosine hydroxylase and
VMAT2 have been found in CD163+ human macro-
phages from arthritic synovial tissue but not in CD163+
cells from non-arthritic controls [48]. We previously
demonstrated that primary human monocyte-derived
macrophages (MDM) express D2-like DR on the cell
surface and activation of these receptors increases
HIV replication [49]. The effects of dopamine on
human macrophages are not well characterized.
To examine the response of human macrophages to
the increased dopamine levels induced by drug abuse,
we characterized gene and protein expression of DR,
DAT, VMAT2, TH and AADC in MDM. We also stud-
ied dopaminergic effects on cytokine production in both
basal and inflammatory conditions by using untreated
and LPS-treated macrophages. Macrophages have been
shown to express mRNA for all subtypes of DR and have
D3R and D4R on the plasma membrane. Macrophages
also expressed mRNA and protein for DAT, VMAT2,
TH and AADC, with DAT on the plasma membrane
and VMAT2 in cellular membranes. Our data demon-
strated that dopamine treatment significantly increased
IL-6 and CCL2 in both untreated and lipopolysaccharide
(LPS)-treated MDM, increased CXCL8 and IL-10 and
decreased TNF-α in LPS-treated MDM. These data indi-
cate that dopamine is an important mediator of both
macrophage homeostasis and of the response of macro-
phages to injury and infection, and that drug-induced




RPMI-1640 medium and penicillin/streptomycin (P/S)
were from Invitrogen (Carlsbad, CA, USA). LPS from E.
Coli 055:B5, hydroxyethyl piperazineethanesulfonic acid
(HEPES), fish gelatin, β-mercaptoethanol, IgG-free bo-
vine serum albumin (BSA), horse serum, Tween 20 and
dopamine hydrochloride (DA) were obtained from
Sigma-Aldritch (St. Louis, MO, USA). Dopamine was
resuspended at 20 mM in dH2O, aliquoted and stored at
−80°C for up to 2 months before use. Fetal calf serum
(FCS) and human AB serum were from Lonza (Basel,
Switzerland). Macrophage colony stimulating factor (M-
CSF) was from Peprotech (Rocky Hill, NJ, USA). Anti-
bodies used were rabbit polyclonal anti-DR3 (1:250),
rabbit polyclonal anti-DR4 (1:250), rabbit polyclonal
anti-VMAT2 (1:250) and rabbit polyclonal anti-AADC
(1:200) (Millipore, Billerica, MA, USA), rabbit polyclonal
anti-TH (1:500) (Cell Signaling Technology, Danvers,
MA, USA), rabbit polyclonal anti-DAT (1:250 Western
blot, 1:50 Immunofluoresence, Sigma), anti α-tubulin
(1:10,000), fluorescein isothiocyanate (FITC)-conjugated
anti-rabbit secondary antibodies (Sigma), anti-rabbit IgG
and anti-rabbit Na+/K+ ATPase (1:200, Santa Cruz
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Biotechnologies, Santa Cruz, CA, USA). Other reagents
were anti-fade with 4',6-diamidino-2-phenylindole (DAPI),
TRIzol reagent and phalloidin conjugated to Texas red,
obtained from Molecular Probes (Invitrogen).
Generation of primary human macrophages
Human peripheral blood mononuclear cells (PBMC) were
separated from blood obtained from de-identified healthy
donors (New York Blood Center, Long Island City, New
York, USA) by Ficoll-Paque (GE Healthcare, Piscataway,
NJ, USA) gradient centrifugation. After isolation of
PBMC, MDM were obtained either by adherence over 3
days or by using CD14 magnetic beads (EasySep Human
CD14 Positive Selection kit), according to the manufac-
turer’s protocol (Stem Cell Technologies, Vancouver,
Canada). MDM were cultured in RPMI-1640 with 10%
FCS, 5% human AB serum, 10 mM HEPES, 1% P/S, and
M-CSF (10 ng/mL) for 3 days, washed twice with fresh
media, and cultured for another 3 days in fresh media
containing M-CSF. After 6 days in culture cells were
washed again and considered to be mature MDM.
Quantitative RT-PCR
Total RNA was extracted from MDM using TRIzol
(Invitrogen). Purity and concentration were determined
using a Nanodrop spectrophotometer (Nanodrop tech-
nologies, Wilmington, DE, USA). On the same day of
the extraction, 2 μg of RNA were used to synthesize
cDNA from each donor using the iScript cDNA synthe-
sis kit (Bio-Rad Laboratories Inc., Hercules, CA, USA),
generating random cDNA fragments using both oligo-
dT and random primers. FirstChoice Human Brain Total
RNA was used as a positive control (Ambion, Austin,
TX, USA) and samples containing no cDNA served as
the negative controls. Target mRNA was quantified with
the Absolute Blue QPCR SYBR low ROX Mix (Thermo
Scientific). Single-product amplification was confirmed
by melting-curve analysis. Reactions in which the
negative control showed amplification curves that were
detected before 37 cycles were not used. Specific dopa-
minergic and housekeeping genes were amplified from
cDNA by quantitative PCR (qPCR) from 1 μL of cDNA
reaction using gene-specific primers designed using Pri-
mer3 [50] and synthesized by Fisher Custom Oligonu-
cleotides service (Table 1). The specificity of each primer
for the gene of interest and all common splice variants
was confirmed using a nucleotide BLAST search [51].
Immunofluoresence and confocal microscopy
MDM cultured on 35-mm Mat Tek dishes (Mat Tek,
Ashland, MA, USA) were fixed and permeabilized in
70% ethanol for 30 minutes at 4°C. Cells were washed in
PBS, incubated in block solution (0.5 M EDTA, 1%
human AB serum, 2% fish gelatin, 1% Ig-free BSA, 1%
horse serum in H2O) for 30 minutes at room
temperature (RT) and then in primary antibodies (anti-
DAT or isotype-matched controls, all 1:50) overnight at
4°C. Cells were washed with PBS and incubated for 1 hr
at RT with the appropriate secondary antibody conju-
gated to FITC (1:250, Sigma) as well as phalloidin-conju-
gated Texas Red (1:50, Invitrogen). Cover slips were
mounted on Mat Tek dishes using Prolong Gold Anti-
fade reagent with DAPI (Invitrogen). MDM were exam-
ined by confocal microscopy using a Leica microscope
(Wetzlar, Germany).
Subcellular fractionation
Isolation of MDM plasma membrane, total membrane
and cytosolic fractions was performed using a polyethyl-
ene glycol and dextran T-500-based centrifugal gradient
kit, according to the manufacturer's protocol (BioVision
Membrane Protein Extraction kit, Biovision, Mountain
View, CA, USA). For each lysate, 20 to 40 × 106 MDM
cultured at 10 × 106 MDM per dish were used to gener-
ate either a single plasma membrane or total membrane
and cytoplasmic lysate.
Table 1 Primers used for qRT-PCR
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Immunoblotting
Human MDM were lysed with mammalian protein ex-
traction reagent (M-PER, Pierce, Rockford, IL, USA)
with added protease (Halt Protease inhibitor cocktail,
Pierce) and phosphatase inhibitors (Halt Phosphatase In-
hibitor Cocktail, Pierce). For detection of TH and
AADC, lysates were sonicated, centrifuged at 14,000 × g,
and stored at −80°C until used. Loading buffer contain-
ing β-mercaptoethanol was added to lysates that were
then heated to 100°C for 5 minutes. Western blot ana-
lyses were performed using 4 to 12% Nupage polyacryl-
amide gels (Invitrogen). Proteins were transferred to
polyvinylidene fluoride (PVDF) membranes (Invitrogen)
and blots were blocked in Tris-buffered saline (TBS-T)
(1×TBS with 1.2% Tween 20) containing 3% BSA/5% non-
fat powdered milk. Signal was detected using Supersignal
WestPico Chemiluminescent substrate for TH or Super-
signal WestFemto Chemiluminescent substrate for AADC
(Pierce). After probing for TH or AADC, blots were
stripped using Restore PLUS Western Stripping Buffer
(Pierce) and probed for α-tubulin as a loading control.
Plasma membrane and cytosolic lysates from the same
donor were probed for either D3R, D4R or DAT, while
total membrane and cytosolic fractions from the same
donor were probed for VMAT2. Denaturing lysates by
heating altered the mobility of the DR, DAT and VMAT2.
Therefore, in place of heating, lysates were incubated in
loading buffer containing β-mercaptoethanol for 45 min-
utes at RT. Western blots were run as described above,
and after probing for DR or DAT, blots were stripped
and reprobed for Na+/K+ ATPase and α-tubulin to con-
firm the specificity of the membrane isolations.
Quantification of cytokine or chemokine secretion
MDM cultured at 5 × 105 per well in 48-well plates (BD-
Falcon) were incubated for 24 hrs with different concen-
trations of dopamine (20 nM, 200 nM, 2 μM or 20 μM)
in the presence or absence of LPS (1 ng/mL). LPS treat-
ment was used to model inflammation. Controls were
treated with 1 ng/mL LPS without dopamine, or were
untreated. After 24 hours, supernatants were collected,
aliquoted and stored at −80°C. Supernatants were ana-
lyzed for IL-6, CCL2, TNF-α, CXCL8 and IL-10 using
sandwich capture ELISAs was performed according to
the manufacturer's protocol (Duoset ELISA Develop-
ment systems, R&D systems, Minneapolis, MN, USA).
The limits of detection for ELISAs were IL-6, 23.44 pg/
mL, CCL2, 31.25 pg/mL, TNF-α, 15.625 pg/mL, CXCL-
8, 31.25 pg/mL and IL-10, 62.5 pg/mL.
Statistical analyses
Statistical analyses were performed using Prism 5.0
(Graphpad, La Jolla, CA, USA), using either a Wilcoxen
Signed Rank Test (for experiments with N ≥10) or a
two-tailed Student’s T-test (for all other experiments).
P <0.05 was considered significant. To evaluate dopa-
mine mediated changes in each cytokine, the fold-
changes in the amount of each factor upon dopamine
treatment from all donors were pooled and compared
to the combined mean fold-change in the control con-
dition (either untreated MDM or MDM treated with
1 ng/mL LPS), which was set to one.
Results
Primary human macrophages express dopamine
receptors
We previously showed that dopamine treatment of
human macrophages significantly increases HIV repli-
cation [49], and others demonstrated that dopamine
alters cytokine secretion and other functions in ro-
dent macrophages and microglia as well as in human
T-cells. Dopamine mediates its effects principally
through activation of dopamine receptors. Therefore
we examined the expression and localization of DR in
human macrophages. Our previous data demonstrated
D1R and D2R on the surface of MDM [49]. To ex-
pand upon our original studies, we examined human
macrophage mRNA for D3R, D4R and D5R as well as
for D1R and D2R. We also examined the expression
and localization of D3R and D4R on MDM. Protein
expression and localization of D5R was not examined
because of the lack of available antibodies that distin-
guish specifically between D1R and D5R. The mRNA
from MDM isolated from 4 different donors was ana-
lyzed by qRT-PCR for D1R, D2R, D3R, D4R and
D5R, as well as for the housekeeping gene β-actin as
a control for proper PCR amplification. Representative
plots showing the mRNA amplification from a single
donor for each DR or for β-actin (red curves) are
shown in Figure 1. Total Human brain RNA was used
as a positive control in each amplification reaction
(blue curves) and samples containing no cDNA
served as the negative control (green curves) in each
reaction. Among the four donors examined, the ΔCT
relative to β-actin for D1R was 12 +/− 2.4 (mean +/−
SD), for D2R was 16.6 +/− 4.2, for D3R was 12.6 +/−
3.7, for D4R was 14.7 +/− 3.7 and for D5R was
9.6 +/− 3.5. The negative control did not show ampli-
fication curves before 37 cycles in any amplification
reaction.
To demonstrate that D3R and D4R are expressed
on the plasma membrane of MDM, plasma mem-
brane (PM) proteins were examined by western blot-
ting. Representative Western blots show both D3R
(Figure 2A, black arrow, 40 kDA) and D4R
(Figure 2B, black arrow, 48 kDA) in the PM fraction.
The western blots were stripped and probed for the
plasma membrane protein Na+/K+ ATPase, which was
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enriched in the PM fraction, and the cytosolic protein
α-tubulin, which was not found in the PM fraction,
confirming the localization of the DR in the PM.
These data demonstrate that human MDM express
mRNA for all types of DR, and that D3R and D4R
are present in the plasma membrane.
Primary human macrophages express tyrosine
hydroxylase and aromatic amino acid decarboxylase
To determine whether primary human macrophages ex-
press TH and AADC, and therefore have the capacity to
synthesize dopamine, mRNA and protein for both were
examined in human MDM from 4 different donors.
Figure 1 Human macrophages express mRNA for all dopamine receptors (DRs). Quantitative RT-PCR (1A) detected mRNA for D1R, D2R,
D3R, D4R and D5R in monocyte derived macrophages (MMD) isolated from 4 different donors. Representative amplification curves from a single
donor are shown for each DR (red curves) and the housekeeping gene β-actin (red curves). Amplification curves for the positive control (Total
Human brain RNA, blue curves) and the negative control (cDNA negative samples, green curves) are also shown.
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Quantitative RT-PCR was used to amplify mRNA for
TH and AADC, and representative amplification curves
for TH, AADC and β-actin (red curves) from a single
donor are shown in Figure 3A. Total human brain RNA
and cDNA negative samples used as the positive (blue
curves) and negative controls (green curves) are also
shown in each plot. In mRNA derived from four donors,
the ΔCT relative to β-actin was 14 +/− 4.6 for TH and
21.1 +/− 3.8 for AADC. The negative control did not
show amplification curves detected before 37 cycles in
any amplification reaction. Western blot analyses
demonstrated both TH and AADC in MDM whole cell
lysate derived from four different donors (Figure 3B,
donors 1, 2, 3, 4 TH approximately 62 kDA, AADC ap-
proximately 50 kDA). Blots were probed for α-tubulin as
a loading control. These data demonstrate that primary
human macrophages express the proteins required to
synthesize dopamine.
Primary human macrophages express dopamine
transporter and vesicular monoamine transporter 2
To determine whether MDM have the capacity to take
up dopamine from the extracellular space to the cyto-
plasm and transport it into storage vesicles, we analyzed
expression of DAT and VMAT2 mRNA and protein
from MDM derived from three different donors. Dopa-
mine transporter was also examined by immunofluore-
sence. Using qRT-PCR, DAT and VMAT2 mRNA were
detected in all donors examined, and representative
amplification curves of these genes (red curves) and the
housekeeping gene β-actin (red curve) are shown in
Figure 4A. Total Human brain RNA (blue curves) and
cDNA–negative (green curves) samples were used as the
positive and negative controls, respectively. The ΔCT
Figure 2 Human macrophages express dopamine receptors
(DRs) 3 and 4 on the plasma membrane. Western blot analysis of
isolated plasma membrane (PM) and cytoplasmic (Cyto) proteins
from monocyte-derived macrophages (MDM) demonstrated that
D3R (2B, black arrow, ~ 40 kDA) and D4R (2C, black arrow,~ 48 kDA)
were expressed in the PM. Specificity of the membrane protein
isolation was confirmed by enrichment of Na+/K+ ATPase and lack of
α-tubulin in plasma membrane fractions (B, C).
Figure 3 Human macrophages express tyrosine hydroxylase and aromatic amino acid decarboxylase. Quantitative RT-PCR (A) detected
mRNA for tyrosine hydroxylase (TH) and aromatic amino acid decarboxylase (AADC) in monocyte derived macrophages (MDM) isolated from four
different donors. Representative amplification curves from a single donor (A) are shown for TH, AADC (red curves) and the housekeeping gene β-
actin (red curves). Amplification curves for the positive control (Total Human brain RNA, blue curves) and the negative control (cDNA negative
samples, green curves) are also shown (A). Western blot analysis of MDM lysate from donors 1, 2, 3 and 4) (B) showed expression of TH
(approximately 62 kDA) and AADC (approximately 50 kDA) in all donors examined.
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relative to β-actin was 11.2 +/− 5.7 for DAT and 8.5 +/−
3 for VMAT2. The negative control did not show ampli-
fication detected before 37 cycles in any reaction.
Western blot analysis of plasma membrane proteins
isolated from three different donors shows DAT
(Figure 4B, donors 1, 2, 3, black arrow, approximately 70
kDA) and VMAT2 (Figure 4C, black arrow, approxi-
mately 48 kDA) in the membrane fraction (PM, plasma
membrane or TM, total membrane). We probed for
VMAT2 in the total membrane fraction rather than the
PM fraction because VMAT2 is found in cytoplasmic
vesicles (ref for VMAT2). Neither protein was found in
the cytosolic fraction (Cyto). Purity of the membrane
isolation was confirmed by enrichment of Na+/K+
ATPase and the absence of α-tubulin in the membrane
fractions. Dopamine transporter expression on MDM
was also demonstrated by immunofluorescence.
Figure 4D, panels 1–3, show DAT on the cell surface
and in the cytoplasm, with cell nuclei labeled blue (4D-1
and 4D-4, DAPI), actin red (4D-2 and 4D-5, Texas Red)
and DAT labeled green (4D-3, FITC). The isotype-
matched control antibody had minimal to no reactivity
(4D-6, FITC). These data demonstrate that primary
human macrophages express DAT and VMAT2 mRNA
and protein, that DAT is expressed in the plasma mem-
brane and VMAT2 is expressed in cellular membranes,
and suggest that macrophages may be able to take up
extracellular dopamine and store it in vesicles.
Activation of dopamine receptors modulates macrophage
cytokine secretion
To examine the effect of dopamine on cytokine secre-
tion, MDM from different donors were treated with 20
nM, 200 nM, 2 μM or 20 μM dopamine for 24 hours in
either media alone or in the presence of LPS (1 ng/mL).
Control cells were treated with media alone (Untx) or
LPS in the absence of dopamine. LPS was used to model
the effect of dopamine on macrophage cytokine secre-
tion in an inflammatory environment. Supernatants from
each treatment condition were analyzed by ELISA for se-
cretion of IL-6, CCL2, TNF-α, CXCL8 or IL-10. These
cytokines were selected because of their important roles
in the neuroinflammation and in the development of
neurological diseases such as HAND and Alzheimer’s
Disease. Cytokine secretion in control MDM was com-
pared to cytokine secretion in cells treated with different
concentrations of dopamine. It is important to note that
the variability inherent in studying primary human cells
Figure 4 Macrophages express the dopamine transporter and vesicular monoamine transporter 2. Quantitative RT-PCR (A) detected
mRNA for the dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) in monocyte-derived macrophages (MDM) isolated
from four different donors. Representative amplification curves from a single donor (A) are shown for DAT, VMAT2 (red curves) and the
housekeeping gene β-actin (red curves). Amplification curves for the positive control (Total Human brain RNA, blue curves) and the negative
control (cDNA negative samples, green curves) are also shown (A). Western blot analysis of isolated MDM plasma membrane (PM) and
cytoplasmic (Cyto) proteins from three different donors demonstrated that DAT (B, black arrow, approximately 70 kDA) was expressed in the
plasma membrane of MDM. Western blot analysis of isolated MDM total membrane (TM) and cytoplasmic (Cyto) proteins demonstrates
expression of VMAT2 (4C, black arrow, approximately 48 kDA) in MDM membranes. Specificity of plasma and total membrane isolation was
confirmed by enrichment of Na+/K+ ATPase and lack of α-tubulin reactivity in membrane fractions (B, C). Expression of DAT is also shown in MDM
stained for DAT (4D-3, FITC) or the isotype matched negative control antibody (3D-6, FITC). Cell nuclei were stained with DAPI (4D-1, -4, blue),
actin was stained with Phalloidin-Texas Red (4D-2,-5, red), and the DAT or the isotype control were stained with FITC (4D-3, 6, green). Scale bars
represent 23.81 μM.
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Figure 5 Dopamine modulates macrophage cytokine secretion. Monocyte-derived macrophages (MDM) were treated with different
concentrations of dopamine (grey bars, 20 nM, 200 nM, 2 uM, and 20 uM) for 24 hrs. Control cells were treated with media (Untx, white bars).
Supernatants were collected after treatment and analyzed for IL-6 (A, B, n = 11), CCL2, (C, D,n = 13) and CXCL8 (E, F, n = 6) by ELISA. The dot
graphs (A, C, E) show the concentration of each cytokine in the culture medium after 24 hours for all donors examined, demonstrating the inter-
donor variability in the secretion of each cytokine. Bar graphs (B, D, F) represent the mean of the dopamine–mediated fold change in cytokine
from all donors relative to the control (Untx), which is set to 1. Significance was determined using a Wilcoxon Signed Rank Test (B, D) or two-
tailed Student’s T-test (H). * P >0.05,** P >0.01.
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resulted in large inter-donor differences in cytokine se-
cretion. In MDM not treated with LPS, dopamine had
the most pronounced effect on IL-6, significantly in-
creasing its elaboration by 2 and 3 fold at 2 and 20 μM
dopamine respectively (n = 11, Figure 5A, 5B). Dopa-
mine also significantly increased macrophage secretion
of CCL2 by approximately 1.3 fold at 2 μM and 20 μM
dopamine (n = 13, Figure 5C, 5D), but did not have any
significant effect on secretion of CXCL8 (n = 6,
Figure 5E, 5F). Changes in TNF-αor IL-10 secretion
were not examined in non-LPS treated macrophages be-
cause secretion of these cytokines was undetectable in
samples from many donors. In all MDM, LPS treatment
induced a significant increase in the secretion of all cyto-
kines except CCL2, as compared to MDM not treated
with LPS. Dopamine significantly increased IL-6 secre-
tion in LPS treated macrophages by 1.5 fold at 200 nM
(n = 11, Figure 6A, 6B). Dopamine modulated CCL2
production in LPS treated macrophages similarly to
non-LPS treated macrophages, significantly increasing
CCL2 production approximately 1.4 fold at 200 nM and
2 μM dopamine, although not at 20 μM dopamine (n =
10, Figure 6C, 6D). The only cytokine decreased by
dopamine treatment was TNF-α, as dopamine signifi-
cantly reduced secretion of this cytokine approximately
−1.3 to −1.4 fold in LPS treated macrophages at all con-
centrations examined (n = 12, Figure 6E, 6F). Unlike in
non-LPS treated cells, dopamine significantly increased
CXCL8 in macrophages treated with LPS by approxi-
mately 1.3 fold at both 2 μM and 20 μM (n = 10,
Figure 6G, 6H). Dopamine also significantly increased
IL-10 secretion in LPS treated cells approximately 1.7
fold at 2 μM and 20 μM (n = 10, Figure 6I, 6J), and
trended towards increases at lower dopamine concentra-
tions, although these changes were not significant. These
data demonstrate that dopamine regulates cytokine se-
cretion in primary human macrophages.
Discussion
Dopamine is an immunoregulatory molecule, modulat-
ing the functions of rodent macrophages as well as
human T-cells, in addition to its role as a neurotransmit-
ter. Its effects on human macrophages and microglia
had not been well characterized. We hypothesized that
in the CNS of drug abusers or others with increased
extracellular dopamine, dopamine–mediated changes in
macrophage or microglial function would alter the de-
velopment of neuroinflammation and the progression of
several neurological diseases. We therefore determined
whether human primary MDM express dopamine recep-
tors and the dopaminergic machinery to respond to,
synthesize, and take up dopamine. We showed that
MDM express mRNA for all DR, as well as for DAT,
VMAT2, TH and AADC. We demonstrated that MDM
express D3R and D4R as well as DAT on the cell sur-
face, VMAT2 on cellular membranes, and TH and
AADC. We also showed that dopamine modulates the
secretion of cytokines in both untreated and LPS-treated
MDM. These findings indicate that macrophages express
the proteins needed to respond to dopamine and that
dopamine modulates macrophage functions.
Macrophages in the CNS in close proximity to neu-
rons [52] are likely to be exposed to dopamine during
spillover from the releasing synapse into the extrasynap-
tic space [53,54]. Extracellular dopamine concentrations
in the human brain are not well characterized, but in
rats the basal levels are estimated to be between 10 and
30 nM [4,54] and can be increased to 250 nM with a
single electrical stimulus [3]. In both rodent and primate
models, cocaine and methamphetamine increase extra-
cellular dopamine in different regions of the brain
[1,2,55] and studies using cyclic voltammetry measured
drug-induced dopamine flux to be as high as 500 nM -
5 μM [56-58]. To model the effects of dopamine on
macrophages in the brains of drug abusers and others
with increased CNS dopamine, the concentrations of
dopamine used in this study range from 20 nM to
20 μM. We previously demonstrated that 20 μM dopa-
mine increases HIV replication in human macrophages
[49]. Many other studies showed that dopamine concen-
trations within this range modulate different functions
in rodent macrophages and microglia, as well as in
human T cells [17-24]. Dopamine mediates its effects
primarily through activation of DR on the PM [30], al-
though other dopamine mediated signaling pathways
have been suggested by studies in rodent macrophages
[22]. Dopamine receptor mRNA or protein was shown
on rodent microglia [19] and human T-cells [20,40,59].
In T-cells, specific DR were shown to effect cytokine se-
cretion [20], activation of regulatory T-cells [17] or β1
integrin function [21]. In human macrophages DR sub-
types had not been fully characterized. Our study shows
that primary human macrophages have mRNA for all
five subtypes of DR and express D3R and D4R in the
PM. Our previous work showed MDM express D1R and
D2R on the cell surface and showed specific activation
of D2-like DR induces MAP kinase signaling [49]. An-
other study showed D1R in human macrophages [60],
although its localization was not characterized. These
studies demonstrate that DR are expressed on the sur-
face of human macrophages and suggest that distinct
DR subtypes may differentially modulate macrophage
functions.
The effects of dopamine can also be regulated by DAT,
VMAT2, TH and AADC. Our data show that primary
human MDM express these proteins,. The dopamine
transporter is localized to the PM and VMAT2 is in cel-
lular membranes. Whether these proteins have a role in
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macrophage function is still unclear, as DAT was not
found in a rodent macrophage cell line [61], while
VMAT2 was expressed in promyelocytic human U937
cells but not in monocytic THP-1 cells [46,48]. However,
functional DAT is expressed in human T-cells [62-64].
Tyrosine hydroxylase was detected in rodent macro-
phages [65], human T-cells [17] and human macro-
phages from arthritic tissue, although not in
macrophages from non-arthritic controls [48], while
AADC was found in human U937 cells and human T-
cells [38,47]. Dopamine production has not been charac-
terized in human macrophages, but low amounts of
dopamine are synthesized in rodent macrophages
[65,66] and human PBMC [17,40,67], and AADC in
U937 cells is enzymatically active [47]. Dopamine uptake
in human macrophages has also not been studied, but
dopamine has been detected in cytoplasmic vesicles of
human U937 cells and in rodent macrophages [66,67].
Together with our data, these studies suggest that
human macrophages may take up, store, and synthesize
dopamine, but the functional consequences of these
actions remain unclear. In human CD4+/CD25+ regula-
tory T-cells, dopamine release and reuptake regulates an
autocrine/paracrine loop through activation of D1-like
DR to regulate IL-10 and TGF-β production [17].
Our data show that dopamine also regulates IL-10
production in MDM, suggesting dopamine synthesis
and/or dopamine uptake, storage and release may par-
ticipate in regulation of macrophage cytokine produc-
tion. Our data demonstrate that dopamine treatment
alters macrophage production of IL-6, CCL2, TNF-α,
CXCL8 and IL-10. We found that 2 and 20 μM dopamine
significantly modulated secretion of all cytokines exam-
ined, while lower concentrations (20 and 200 nM) only
altered TNF-α, IL-6 and CCL2 production by LPS-treated
MDM. Lower concentrations of dopamine also showed a
trend towards modulation of both IL-6 in untreated
MDM and IL-10 in LPS treated MDM, but these effects
were not significant. Dopaminergic modulation of cyto-
kines has been shown in both rodent macrophages [18,22]
and human T-cells [20,68] using similar concentrations of
dopamine or using DR agonists. One study showed signifi-
cant decreases in IL-2, IL-4 and IFN-γ production from
anti-CD3 activated human T-cells at lower dopamine
levels (5–25 nM) [43]. The trend towards higher concen-
trations of dopamine being needed to induce significant
cytokine secretion suggests that dopamine concentrations
must be elevated above physiological levels to alter macro-
phage cytokine secretion.
Treatment of macrophages with LPS was used to
model inflammatory conditions within the CNS. The
effects of dopamine on LPS-treated macrophages indi-
cate that macrophages in an inflammatory environment
may respond differently to dopamine than do macro-
phages in homeostatic conditions. Elevated levels of LPS
during HIV infection [69], and in individuals with HIV-
associated dementia [70], suggest that macrophages in
people with NeuroAIDS may respond differently to
dopamine due to LPS-mediated activation. In our study,
CXCL8 was signifcantly increased by dopamine treat-
ment of LPS-treated MDM but was unaffected by dopa-
mine in untreated cells. In contrast, treatment with 2
and 20 μM dopamine increased IL-6 2-to-3 fold in un-
treated cells, but increased IL-6 only 1.5 fold, and only
at 200 nM dopamine, in LPS-treated macrophages.
These data suggest that LPS activation of MDM primes
the cells to respond differently to dopamine than non-
LPS treated cells. Further investigation of changes in
dopamine–mediated modulation of macrophage func-
tions in response to inflammatory stimuli is an area of
ongoing research. Dopamine mediated changes in cyto-
kines have important implications for neuroinflamma-
tion. Elevated levels of CCL2 and CXCL8 may result in
recruitment of peripheral blood monocytes, T-cells and
neutrophils [71,72], increased blood brain barrier perme-
ability [72,73] and altered migration of CNS cells [74].
Increases in IL-6, CCL2 and CXCL8 are associated with
activation of perivascular macrophages and glia, and
with the development of neurological diseases such as
HAND, Alzheimer’s disease, Parkinsons’s or Hunting-
ton’s disease, and multiple sclerosis [26,75-78].
Changes in cytokine production may also be beneficial,
as decreases in TNF-α and increases in both IL-10 and
CCL2 could limit neuroinflammation or be neuroprotec-
tive, depending on the kinetics and localization of their
expression. For example, in Parkinson’s disease, in which
TNF-α plays a central role in the loss of dopaminergic
neurons [79], decreases in this cytokine could reduce
(See figure on previous page.)
Figure 6 Dopamine modulates LPS-induced macrophage cytokine secretion. MDM were treated with different concentrations of dopamine
(grey bars, 20 nM, 200 nM, 2 μM, and 20 μM) in conjunction with 1 ng/mL of LPS. Control cells (Control, blue bars) were treated with LPS only,
while untreated MDM were treated with vehicle (Untx, white bars). Supernatants were collected after 24 hrs of treatment and analyzed for IL-6 (A,
B, n = 11), CCL2 (C, D, n = 10), TNF-α (E, F, n = 12), CXCL8 (G, H, n = 10) and IL-10 (I, J, n = 10) by ELISA. The dot graphs (A, C, E, G, I) show the
concentration of each cytokine in the culture medium after 24 hours for all donors examined, demonstrating the inter-donor variability in the
secretion of each cytokine. Bar graphs (B, D, F, H, I) represent the mean of the dopamine mediated fold change in cytokines from all donors
relative to the control (LPS only), which was set to 1. Significance was determined using a Wilcoxon Signed Rank Test (B, D) or two–tailed
Student's t-test (H). * P >0.05, ** P >0.01, *** P >0.001.
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neuronal toxicity and slow disease progression [80].
Increases in CCL2 inhibit HIV-Tat induced apoptosis in
neurons and astrocytes [81] and increased IL-10 facili-
tates neuronal recovery after traumatic brain injury by
reducing inflammatory cytokine production [82]. Thus,
changes in CNS dopamine which modulate macrophage
secretion of the cytokines examined in this study may
alter the CNS response to injury and infection, and sig-
nificantly affect the pathogenesis of several neurological
diseases [25,75,83].
Conclusion
Macrophages are central to CNS homeostasis, immune
and inflammatory response. Thus, the effects of elevated
dopamine on macrophages may have a profound impact
on neuroinflammation and the CNS response to insult
as well as on the development of neurological diseases
including Alzheimer’s disease and HAND. The use of il-
legal drugs such as cocaine and methamphetamine
increases CNS dopamine, and could therefore alter the
development of neuroinflammation and modulate
macrophage functions. Several therapeutic drugs also in-
crease extracellular dopamine in the CNS, and may
therefore have broader effects than treatment of a spe-
cific disease or condition. More detailed analyses of the
actions of dopamine on macrophages are important for
our understanding of the effects of legal and illegal
dopaminergic drugs on the CNS. These studies will ad-
dress the efficacy and safety of long-term treatment regi-
mens as well as facilitate the development of novel
interventional strategies for neurologic diseases in the
context of drug abuse.
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